• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Discontinuing statins near end of life not associated with adverse outcomes

byAnees DaudandJames Jiang
March 25, 2015
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Amongst a population of patients enrolled in palliative care secondary to advanced life-limiting illness, discontinuing their statin therapy did not lead to an increased proportion of deaths within the first two months, or time to first cardiovascular-related event.

2. While there was a trend towards improved quality of life amongst those who discontinued statin therapy, there were no significant differences observed between the two groups in other patient-centered outcomes.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Modern, evidence based medicine does well with determining when to start a variety of medications for different comorbidities. However, there is not as much guidance on when to potentially stop these medications, especially for those with advanced life-limiting illness. At these later stages, polypharmacy often places a higher burden compared to the potential benefit of the individual medications. Statin medications, which are used for primary and secondary prevention of cardiovascular disease, are one group of medications thought to be unnecessary in these late stages of life. This study, which was a randomized study amongst a palliative care population, showed that continuing versus discontinuing statin therapy did not affect the proportion of deaths in the first two months, or the time to first cardiovascular event during the study period. While there was a trend towards improved quality of life amongst those who discontinued statin therapy, there were no significant differences observed between the two groups in other patient-centered outcomes.

The strength of the study was in its design, which included randomization and multicenter involvement. The weakness includes the fact that investigators changed the primary outcomes midway through the study because of the limited number of patients reaching that initial end point. Also, including only palliative care patients, many of whom were hospice-enrolled, limits the generalizability of the results.

Click to read the study in JAMA Internal Medicine

Relevant Reading: Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy

RELATED REPORTS

Systematic review and meta-analysis of statin-induced reduction in LDL-C demonstrates modest absolute benefits

#VisualAbstract: Capecitabine in addition to best supportive care improves progression-free survival in metastatic nasopharyngeal carcinoma

Three-step support strategy reduces prolonged grief in relatives after death of intensive care unit patients

In-Depth [randomized controlled trial]: Patients for this study were chosen from 15 Palliative Care Research Cooperative Group member sites in the United States. The study was conducted from 2011 to 2013. There were a total of 381 patients enrolled in the study, with 189 discontinuing statin therapy and 192 continuing therapy. Inclusion criteria were adults who had been on statin therapy for at least three months prior to starting the study, who had a life-expectancy of between one month and one year as determined by their physician, and a recent deterioration in their functional status. Exclusion criteria included a recent cardiovascular event or intolerance to statin therapy. The primary endpoint was proportion of deaths within 60 days of study enrollment. Secondary endpoints included overall survival, time to first cardiovascular event, and a number of patient-centered outcomes.

The mortality rates in the first 60 days in the discontinuation and continuation groups were not significantly different (23.8% vs. 20.3%; 95%CI -3.5 to 10.5%; p = 0.36). There was also no significant difference in time to first cardiovascular-related event (p = 0.64). In the patient-centered outcomes, there was a higher Total McGill Quality of Life (QOL) amongst the discontinuation group (7.11 vs. 6.85; p = 0.04), but there was no difference in the single question assessment overall QOL (6.53 vs. 6.35; p = 0.44). There was also no difference in physical symptoms or performance status between the groups.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: palliative carestatin
Previous Post

Early, goal-directed therapy does not reduce mortality in septic shock [ProMISe trial]

Next Post

Medical therapy beneficial over stent placement for intracranial arterial stenosis

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Cardiology

Systematic review and meta-analysis of statin-induced reduction in LDL-C demonstrates modest absolute benefits

April 7, 2022
#VisualAbstract: Cutaneous squamous cell carcinoma with satellitosis or in-transit metastasis shows similar survival to node-positive disease
StudyGraphics

#VisualAbstract: Capecitabine in addition to best supportive care improves progression-free survival in metastatic nasopharyngeal carcinoma

March 2, 2022
Chronic Disease

Three-step support strategy reduces prolonged grief in relatives after death of intensive care unit patients

February 23, 2022
Pediatric palliative care outcome measures often miss quality of life
Chronic Disease

Psychological experiment suggests genetic testing may influence neonatologists’ clinical decision-making

February 16, 2022
Next Post
Stroke expansion following intra-arterial therapy may explain worse outcomes

Medical therapy beneficial over stent placement for intracranial arterial stenosis

Active smoking cessation intervention may provide tangible results [Project CLIQ]

Plain cigarette packaging linked to decrease in appeal among teens

Ebola outbreak projected to exceed 20,000 cases by November

Ebola virus vaccine based on 2014 epidemic strain shown to be safe and immunogenic

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.